Home > Compound List > Product Information
1-Piperidinecarbonyl chloride_Molecular_structure_CAS_13939-69-0)
Click picture or here to close

1-Piperidinecarbonyl chloride

Catalog No. 518522 Name Sigma Aldrich
CAS Number 13939-69-0 Website http://www.sigmaaldrich.com
M. F. C6H10ClNO Telephone 1-800-521-8956
M. W. 147.6027 Fax
Purity 97% Email
Storage Chembase ID: 151333

SYNONYMS

Title
1-哌啶酰氯
IUPAC name
piperidine-1-carbonyl chloride
IUPAC Traditional name
piperidine-1-carbonyl chloride
Synonyms
NSC 50227
N-Chloroformylpiperidine

DATABASE IDS

PubChem SID 24874029
MDL Number MFCD00973554
CAS Number 13939-69-0

PROPERTIES

Empirical Formula (Hill Notation) C6H10ClNO
Purity 97%
Boiling Point 242 °C(lit.)
Density 1.18 g/mL at 25 °C(lit.)
Flash Point 110 °C
Flash Point 230 °F
Refractive Index n20/D 1.459(lit.)
GHS Pictograms GHS05
GHS Signal Word Danger
GHS Hazard statements H314
European Hazard Symbols Corrosive Corrosive (C)
MSDS Link Download
Personal Protective Equipment Faceshields, full-face respirator (US), Gloves, Goggles, multi-purpose combination respirator cartridge (US), type ABEK (EN14387) respirator filter
GHS Precautionary statements P280-P305 + P351 + P338-P310
RID/ADR UN 3265 8/PG 3
Risk Statements 34
Safety Statements 26-27-36/37/39-45
Hazard Class 8
UN Number 3265
Packing Group 3
German water hazard class 3

DETAILS

Description (English)
Packaging
5 g in glass bottle
Application
Reactant for synthesis of: A coumarin-based HIV-1 Vpr inhibitor1 Antitumor agents as potent chemosensitizers2 Oxime carbamates as reversible inhibitors of fatty acid amide hydrolase3 Dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes4 Bisarylmaleimide glycogen synthase kinase-3 inhibitors5 Lysosomal acid lipase inhibitors and potential Niemann-Pick type C disease therapeutics6
Description (简体中文)
包装
5 g in glass bottle
Application
Reactant for synthesis of: A coumarin-based HIV-1 Vpr inhibitor1 Antitumor agents as potent chemosensitizers2 Oxime carbamates as reversible inhibitors of fatty acid amide hydrolase3 Dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes4 Bisarylmaleimide glycogen synthase kinase-3 inhibitors5 Lysosomal acid lipase inhibitors and potential Niemann-Pick type C disease therapeutics6

REFERENCES